secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001628280-25-011830
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth
--------------------------------------------------------------------------------

- Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).
- FY2024 revenue $573.3M (+11.9%); net loss $43.8M vs ($121.2M); adj EBITDA $108.9M (+22.5%).
- FY2025 guidance: net sales $560-570M, adj EBITDA $112-116M, non-GAAP EPS $0.64-$0.68.
- Debt reduced by $48.3M in Q4; Advanced Rehabilitation Business divested for $24.7M proceeds.
- Pain Treatments and Surgical Solutions each delivered double-digit revenue growth for fifth straight quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828025011830/0001628280-25-011830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828025011830/bvs-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-011830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer